Hematopoietic progenitor cells (HPCs) harvested from the marrow [HPC(M)] or mobilized and collected from the blood by apheresis [HPC(A)] are used for autologous and most allogeneic hematopoietic stem cell transplants. Autologous HPCs are also used for regenerative medicine and other cell-based therapies. Precollection assessments and optimal management require an understanding of baseline risks, potential toxicities and additional effects of medical co-morbidities on anesthesia and marrow harvest [for HPC(M)] or on mobilizing agents and apheresis [for HPC(A)]. Donor autonomy and advocacy, including psychosocial effects of recruitment, consent, management and research participation, must also be ensured. In this audioconference, case studies, safety and outcome data and ethical standards for donors and patients undergoing HPC collection will be reviewed as a framework for discussions of higher risk individuals with significant medical co-morbidities and/or ethical considerations. Strategies for risk stratification, medical management and donor advocacy will be discussed.